This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 May;73(5):791-792.

doi: 10.1016/j.eururo.2018.01.028. Epub 2018 Feb 12.

Overactive Bladder: Advancement or More of the Same

Gopal Badlani¹

Affiliations

Affiliation

¹ Urology Department, Wake Forest University, Winston-Salem, NC 27157, USA; Urology Section, Veterans Affairs, Salisbury, NC, USA. Electronic address: gbadlani@wakehealth.edu.

PMID: 29449033
DOI: 10.1016/j.eururo.2018.01.028

Editorial

Overactive Bladder: Advancement or More of the Same

Gopal Badlani. Eur Urol. 2018 May.

. 2018 May;73(5):791-792.

doi: 10.1016/j.eururo.2018.01.028. Epub 2018 Feb 12.

Author

Gopal Badlani¹

Affiliation

¹ Urology Department, Wake Forest University, Winston-Salem, NC 27157, USA; Urology Section, Veterans Affairs, Salisbury, NC, USA. Electronic address: gbadlani@wakehealth.edu.

PMID: 29449033
DOI: 10.1016/j.eururo.2018.01.028

No abstract available

PubMed Disclaimer

Comment on

Vibegron, a Novel Potent and Selective β₃-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.
Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Yoshida M, et al. Eur Urol. 2018 May;73(5):783-790. doi: 10.1016/j.eururo.2017.12.022. Epub 2018 Feb 1. Eur Urol. 2018. PMID: 29366513 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information